Summary & Overview
HCPCS J7324: Orthovisc Intra-Articular Hyaluronan Injection, Per Dose
HCPCS Level II code J7324 represents a single dose of hyaluronan derivative (Orthovisc) administered by intra-articular injection for viscosupplementation. This code is used nationally to bill for a non-opioid, intra-articular therapy commonly applied in the management of joint pain, particularly degenerative joint disease. Its use affects outpatient and office-based musculoskeletal care delivery and has implications for procedure billing, medical necessity review, and payer coverage policies.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code's clinical purpose and service context, along with national benchmarking elements where available. The publication outlines common billing considerations, payer coverage patterns, and coding relationships relevant to musculoskeletal and rheumatologic care.
This summary prepares clinicians, coders, and policy analysts to understand where J7324 fits within procedure billing, the typical settings in which the service is delivered, and the policy considerations that influence reimbursement and utilization. Data not available in the input is noted where applicable in subsequent sections.
Billing Code Overview
HCPCS Level II code J7324 describes hyaluronan or derivative, Orthovisc, for intra-articular injection, per dose. The service involves intra-articular administration of a hyaluronan derivative intended to provide viscosupplementation within a joint space.
Service type: Intra-articular hyaluronan injection (viscosupplementation)
Typical site of service: Outpatient clinic, physician office, or ambulatory surgical center for joint injection procedures
Clinical & Coding Specifications
Clinical Context
A 64-year-old patient with symptomatic osteoarthritis of the knee presents to an orthopedic clinic after months of conservative management including physical therapy, oral NSAIDs, and activity modification with persistent pain and functional limitation. The clinician documents localized knee joint pain, stiffness, and reduced range of motion consistent with degenerative joint disease. After shared decision-making, a plan is made to perform an intra-articular viscosupplementation injection using J7324 (Hyaluronan or derivative, ORTHOVISC, per dose). The procedure is performed in an outpatient clinic procedure room or ambulatory surgery center: the patient is positioned supine, the knee is prepped with antiseptic, local anesthetic is administered to the skin and subcutaneous tissues, and a single intra-articular injection of the hyaluronan product is delivered using aseptic technique under anatomic landmark guidance or ultrasound as documented. Post‑procedure instructions, observation for immediate adverse reaction, and activity guidance are provided prior to discharge. The encounter documentation includes indication (osteoarthritis of the knee), informed consent, laterality (RT/LT), product name and dose, administration route, lot number if required, and any immediate complications.
Coding Specifications
- For
J7324, common clinically relevant modifier use is listed below.
| Modifier | Description |
|---|